Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
Crawford, James J
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. [electronic resource] - Journal of medicinal chemistry 03 2018 - 2227-2245 p. digital
Publication Type: Journal Article
1520-4804
10.1021/acs.jmedchem.7b01712 doi
Agammaglobulinaemia Tyrosine Kinase--antagonists & inhibitors
Animals
Anti-Inflammatory Agents--pharmacokinetics
Arthritis, Experimental--drug therapy
Arthritis, Rheumatoid--drug therapy
Dogs
Drug Discovery
Humans
Lupus Erythematosus, Systemic--drug therapy
Madin Darby Canine Kidney Cells
Models, Molecular
Molecular Structure
Piperazines--pharmacokinetics
Protein Kinase Inhibitors--pharmacokinetics
Pyridones--pharmacokinetics
Rats
Rats, Inbred Lew
Rats, Sprague-Dawley
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. [electronic resource] - Journal of medicinal chemistry 03 2018 - 2227-2245 p. digital
Publication Type: Journal Article
1520-4804
10.1021/acs.jmedchem.7b01712 doi
Agammaglobulinaemia Tyrosine Kinase--antagonists & inhibitors
Animals
Anti-Inflammatory Agents--pharmacokinetics
Arthritis, Experimental--drug therapy
Arthritis, Rheumatoid--drug therapy
Dogs
Drug Discovery
Humans
Lupus Erythematosus, Systemic--drug therapy
Madin Darby Canine Kidney Cells
Models, Molecular
Molecular Structure
Piperazines--pharmacokinetics
Protein Kinase Inhibitors--pharmacokinetics
Pyridones--pharmacokinetics
Rats
Rats, Inbred Lew
Rats, Sprague-Dawley